Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 11;27(8):941–950. doi: 10.1111/cns.13656

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. CNS Neuroscience & Therapeutics Published by John Wiley & Sons Ltd.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Intracerebroventricular infusion of 5‐HT and 5‐HT 1A or 2C receptor agonists or antagonists changed the emergence time of isoflurane anesthesia. A, Verification of cannula track for intracerebroventricular infusion. B, Experimental protocol of assessment of time to RORR. C, Intracerebroventricular application of 5‐HT shortened the emergence time in a dose‐dependent manner (P = 0.0049). D, Intracerebroventricular application of 5‐HT 1A receptor agonist shortened the emergence time in a dose‐dependent manner (P = 0.0053). E, Intracerebroventricular application of 5‐HT 1A receptor antagonist prolonged the emergence time in a dose‐dependent manner (P < 0.001). F, Intracerebroventricular application of 5‐HT 2A/2C receptor agonist shortened the emergence time in a dose‐dependent manner (P = 0.0470). G, Intracerebroventricular application of 5‐HT 2A receptor had no effect on the emergence time (P = 0.8154). H, Intracerebroventricular application of 5‐HT 2C receptor antagonist prolonged the emergence time in a dose‐dependent manner (P < 0.001) (*P < 0.05, **P < 0.01, and ***P < 0.001, one‐way ANOVA followed by Tukey's post hoc test)